Investment Rating - The report does not explicitly state an investment rating for the industry [1]. Core Insights - The solid-state battery industry is advancing, with the release of the "Solid-State Battery Determination Method" standard by the China Automotive Engineering Society, which clarifies definitions and testing methods, paving the way for technological upgrades and industrial applications. Notable developments include BMW's first solid-state electric vehicles undergoing testing and domestic companies like Jinlongyu signing orders for high-energy density solid-state battery cells [3][4]. - The humanoid robot sector is gaining traction, highlighted by the first humanoid robot combat competition, which is expected to enhance interest in the sector. Recent demonstrations by Tesla and Figure's humanoid robots working in factories have contributed to this momentum [3][4]. - The photovoltaic inverter market shows positive demand trends, with China's inverter exports reaching $810 million in April 2025, a 17% year-on-year increase, and a 28% month-on-month increase. European inverter exports also saw significant growth, indicating a recovery in demand [3][4]. Summary by Sections Market Overview - In the past week, the mechanical equipment, electric power equipment, and automotive industry indices experienced declines of -2.48%, -0.71%, and an increase of +1.24%, respectively, ranking them 30th, 16th, and 2nd among 31 Shenwan primary industries [8][10]. Industry News and Key Company Announcements - The humanoid robot combat competition is set to showcase advanced robotics technology and promote industrial upgrades [18]. - Innovations in solar cell materials, particularly perovskite technology, have achieved stable mass production, marking a significant advancement from laboratory to industrial application [16]. - The total installed power generation capacity in the country reached 3.49 billion kilowatts by the end of April, with solar power capacity growing by 47.7% year-on-year [16].

Investment Rating - The report provides a positive outlook on the pharmaceutical and biotechnology sector, indicating a systematic value reassessment for innovative drugs [2][3]. Core Viewpoints - The innovative drug sector is experiencing a systematic value reassessment, highlighted by a significant licensing agreement between Sanofi and Pfizer worth up to $60.5 billion, which includes an immediate investment of $100 million in Sanofi's stock [3][12]. - The report notes that since 2025, there has been a continuous stream of progress and business development (BD) news regarding innovative drug stocks, reflecting an increasing recognition of domestic innovative drugs by overseas pharmaceutical companies [3]. - The report anticipates that the COVID-19 situation is nearing its peak, with recent data showing a slight increase in the positivity rate of COVID-19 tests in Hong Kong, suggesting a potential stabilization in the near future [3][12]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 1.78% from May 19 to May 23, outperforming the Wind All A index (-0.63%) and the CSI 300 index (-0.18%) [8][10]. - Among sub-sectors, other biological products (4.09%), raw materials (4.03%), and medical research outsourcing (3.6%) showed the highest gains, while hospitals (-1.07%), vaccines (0.89%), and blood products (-0.07%) experienced declines [9][10]. - Notably, the stock of Sanofi's affiliate, Sanofi Guojian, surged by 100% during this period [8][11]. Industry News and Key Company Announcements - On May 22, the Hong Kong Health Department reported an increase in COVID-19 virus levels in wastewater monitoring, indicating a rising trend that is beginning to stabilize [12]. - Sanofi announced a significant licensing agreement with Pfizer for the PD-1/VEGF dual antibody SSGJ-707, which is currently in Phase III clinical trials, marking a notable achievement in the global innovative drug landscape [12][14]. - Other companies, such as Kelun Pharmaceutical and GSK, have also made significant advancements with new drug approvals and applications, further indicating a dynamic and evolving industry landscape [14][15].

Investment Rating - The report suggests a positive outlook for the consumer sector, indicating a potential recovery and valuation improvement in the industry [3][4]. Core Insights - The consumer sector showed mixed performance in the week of May 19-23, with notable gains in home appliances and textiles, while food and beverage sectors experienced declines. The Shanghai Composite Index fell by 0.18% during this period [4]. - In April, retail sales increased by 5.1% year-on-year, with significant growth in optional consumption and durable goods. The report highlights that essential consumption, particularly in grain and oil products, maintained high growth rates [4]. - The cleaning appliance market remains robust, with significant sales growth in robotic vacuums and floor washers, indicating a trend towards premiumization and market expansion driven by technological advancements [4]. Market Weekly Review - The consumer sector's weekly performance varied, with home appliances up by 1.21% and food and beverage down by 1.27%. Key stocks that surged included Kuaijishan (+31.37%) and Liren Lizhuang (+53.87%), while stocks like Anji Food (-10.29%) and Huafang Co. (-23.78%) faced declines [4][14][15]. - April's retail sales data showed a 5.1% year-on-year increase, with essential goods like grain and oil growing by 14.0%, and optional goods like cosmetics and jewelry seeing increases of 7.2% and 25.3%, respectively [4][16]. Industry News and Key Company Announcements - The Ministry of Commerce reported that retail sales of home appliances have seen double-digit growth for eight consecutive months, with a 38.8% year-on-year increase in April [16]. - Various cities are implementing policies to boost consumer spending, including subsidies for purchasing home appliances and digital products [17][18]. - Companies like Midea and Hisense are making strategic moves, with Midea's former executive joining Hisense to lead air conditioning business development [19][20].

大消费 [T分析师able_A：uthor 罗鹏 ] 执业证书号：S1030523040001 电话：0755-23602217 邮箱：luopeng@csco.com.cn 研究助理：赵靖 电话：0755-23602217 [Table_ReportDate] 2025 年 5 月 26 日 [Table_ReportType] 大消费行业周报（5 月第 4 周） [Table_Summary] 行业观点： 请务必阅读文后重要声明及免责条款 [Table_Industry] [Table_Title] [Table_Report] [Table_BaseData] 邮箱：zhaojing2@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 4 月社零可选消费表现亮眼 计算机 2019 年 Q3 综合毛利率（%） 9.7 综合净利率（%） 6.9 行业 ROE（%） 25.6 行业 ROA（%） 5.2 利润增长率（%） 4.21 资产负债率（%） 149 期间费用率（%） 4.54 存货周转率（%） 42.56 讯 1) 上周（5/19-5/23）大消费板块表现分化。家用电器、纺织服 饰、 ...

[Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 邮箱：xuyl@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 医药生物 G 创新药开启系统性价值重估 [Table_ReportDate] 2025 年 05 月 26 日 [Table_ReportType] 医药生物行业周报（5 月第 4 周） [Table_S 行业ummary 观点：] 请务必阅读文后重要声明及免责条款 [Table_Industry] [Table_BaseData] 1) 周度回顾。上周（5 月 19 日-5 月 23 日）医药生物板 块收涨 1.78%，跑赢 wind 全 A（-0.63%）和沪深 300 （-0.18%）。从板块来看，其他生物制品（4.09%）、原 料药（4.03%）和医疗研发外包（3.6%）涨幅居前，医 院（-1.07%）、疫苗（0.89%）和血液制品（-0.07%）跌 幅居前。从个股来看，三生国健（100%）为三生制药 ...

[Table_ReportDate] 2025 年 05 月 19 日 [Table_Author] 分析师：李时樟 执业证书：S1030522060001 电话：18065826333 邮箱：lisz@csco.com.cn 分析师：罗晴 执业证书：S1030524110001 电话：13603091122 邮箱：luoqing@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 TMT [Table_Title] 国内两大云厂商大资本同比增长 TMT 行业周报（5 月第 3 周） [Table_S 行业观点： ummary] 请务必阅读文后重要声明及免责条款 [Table_Industry] [Table_ReportType] [Table_BaseData] 1) 周度市场回顾。TMT 板块内一级行业上周（5/12-5/16）涨跌 幅为：通信（-0.12%）、电子（-0.75%）、传媒（-0.77%）、 计算机（-1.26%），TMT 板块整体跑输沪深 300（1.12%）。TMT 板块内涨幅靠前的三级子行业分别为品牌消费电子（1.95%）、 通信网络设备及器件（1.16%）、消费电子 ...

Group 1: Macroeconomic Overview - The joint statement from the China-US Geneva trade talks exceeded expectations, with a 24% tariff on certain goods suspended for 90 days, but the negotiation challenges remain significant[2][12]. - April economic data showed weakness across various indicators, including a 20.9% year-on-year decline in exports to the US, significantly down from a previous increase of 8.9%[5][16]. - The overall market saw a slight increase, with the Shanghai Composite Index rising by 0.76% and the Shenzhen Component Index by 0.52%[11]. Group 2: Financial Market Insights - The bond market experienced an overall rise in yields, with the 10-year government bond yield increasing by 5 basis points, reflecting a limited downward space for long-term rates[11][20]. - April's new social financing was 1.16 trillion yuan, below the expected 1.26 trillion yuan, indicating weaker credit demand amid external pressures[20][21]. - The US stock market saw gains, with the Dow Jones rising by 3.41% and the S&P 500 by 5.27%, driven by improved risk appetite following the trade talks[11][19]. Group 3: Policy and Economic Implications - The Chinese government is expected to continue supporting infrastructure projects, which may provide some stability to the economy despite weak data[5][11]. - The Federal Reserve's potential for rate cuts in 2025 remains uncertain, with inflation pressures expected to ease but still influenced by existing tariffs[19][20]. - The market's short-term outlook is cautious, with limited elasticity due to the uncertainty surrounding tariff negotiations and economic fundamentals[5][17].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it provides insights into various sectors within the equipment manufacturing industry, indicating a cautious outlook for the photovoltaic sector while remaining optimistic about the engineering machinery and humanoid robot sectors [1][2]. Core Insights - The commercial humanoid robot industry is accelerating towards commercialization, driven by advancements in artificial intelligence, a robust supply chain, and supportive policies, leading to a decrease in costs and an anticipated market explosion in service robots across various sectors [2]. - The engineering machinery sector is experiencing stable export growth, supported by the Belt and Road Initiative, with a notable increase in excavator exports, which reached 9,595 units in April, marking a year-on-year increase of 19.3% [2]. - The photovoltaic sector is facing pressure on raw material prices, with recent market rumors about capacity consolidation among leading silicon material companies proving unfounded, leading to a decline in stock prices after an initial spike [2]. Market Performance Review - From May 12 to May 16, the indices for mechanical equipment, electric power equipment, and automotive industries rose by 0.35%, 1.39%, and 2.40% respectively, ranking them 18th, 10th, and 3rd among 31 Shenwan primary industries [7][10]. - The top-performing sub-sectors included passenger vehicles, which rose by 4.43%, and batteries, which increased by 2.47%, while engineering machinery saw a decline of 2.06% [10]. Industry News and Key Company Announcements - The report highlights significant industry events, such as the 4th Changsha International Engineering Machinery Exhibition, which showcased trends towards high-end, intelligent, and green machinery [2]. - Notable announcements include the expected revenue for CSIQ in Q2 2025, projected between $1.9 billion and $2.1 billion, and the anticipated total revenue for the year between $6.1 billion and $7.1 billion [20].

Investment Rating - The report suggests a positive outlook for the consumer sector, particularly in light of recent developments in US-China trade negotiations, which have exceeded market expectations [3][4]. Core Insights - The easing of tariffs between the US and China is expected to provide a significant boost to the light industry export chain, presenting dual opportunities for valuation recovery and performance realization in 2025 [3][4]. - The early start of the 618 shopping festival by major e-commerce platforms indicates a strong push for domestic brands, with significant sales growth observed in local beauty brands [3][4]. Market Weekly Review - The consumer sector showed mixed performance in the week of May 12-16, with notable gains in beauty care (+3.08%), retail (+1.72%), and textiles (+1.01%), while household appliances remained flat and social services declined by -0.54% [4][14]. - Key stocks that led the gains included Jiaoda Onlly (+35.59%) in food and beverage, and Yingfeng Co. (+39.84%) in textiles, while stocks like Wufangzhai (-7.58%) and Heertai (-7.38%) faced declines [4][14]. Industry News and Key Company Announcements - The report highlights the expansion of visa-free travel for citizens from Brazil, Argentina, Chile, Peru, and Uruguay, effective June 1, 2025, which is expected to enhance international tourism and business exchanges [16][17]. - Companies like Li Ziyuan are focusing on stabilizing their supply chains in dairy products, while Midea Group has signed strategic agreements to enhance its market presence in smart indoor climate solutions [17][18].

Investment Rating - The report provides a positive outlook for the pharmaceutical and biotechnology sector, indicating a strong performance compared to the broader market indices [2][3]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.27%, outperforming the Wind All A index (0.72%) and the CSI 300 index (1.12%) [3][8]. - Key sub-sectors such as raw materials (3.79%), in vitro diagnostics (2.25%), and vaccines (1.98%) showed significant gains, while offline pharmacies (-1.24%) and blood products (-0.03%) experienced declines [3][9]. - The report highlights the competitive advantage of tirzepatide over semaglutide in weight loss efficacy, with tirzepatide achieving a 1.47 times greater relative weight reduction and a 64.6% participant rate achieving ≥15% weight loss compared to 40.1% for semaglutide [3][12]. - COVID-19 is entering a phase of periodic outbreaks, with increasing infection rates reported in various regions, prompting recommendations for booster vaccinations among older populations [3][11]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from May 12 to May 16 showed a 1.27% increase, with raw materials leading the gains at 3.79% [8]. - Notable individual stock movements included a significant rise in COVID-19 related stocks like Tuoxin Pharmaceutical, which surged by 45% [11]. Industry News and Key Company Announcements - Recent monitoring data from health authorities in Hong Kong and Singapore indicate a rise in COVID-19 cases, suggesting a potential peak in infections soon [11][13]. - Eli Lilly's tirzepatide clinical trial results demonstrate its superiority over Novo Nordisk's semaglutide in weight loss, indicating a promising market opportunity for obesity treatments [12][13]. - Several companies, including North Sea Kangcheng and Hengrui, have made significant announcements regarding new drug approvals and clinical trials, reflecting ongoing innovation in the sector [13][14].